MATSUKIYOCOCOKARA & CO. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,244 JPY | +1.47% |
|
+0.29% | -10.13% |
| 02-28 | Aeon Co. Plans to Merge Japan Drugstore Unit Welcia With Rival Tsuruha -- 2nd Update | DJ |
| 02-28 | Aeon Co. Plans to Merge Japan Drugstore Unit Welcia With Rival Tsuruha -- Update | DJ |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- With regards to fundamentals, the enterprise value to sales ratio is at 0.81 for the current period. Therefore, the company is undervalued.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Drug Retailers
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -10.13% | 5.86B | C+ | ||
| -29.41% | 10.84B | B | ||
| -29.01% | 6.06B | B | ||
| +7.42% | 6.04B | C | ||
| -0.73% | 4.69B | D- | ||
| +52.19% | 4.29B | - | C | |
| -9.42% | 3.61B | B | ||
| -13.25% | 3.33B | C- | ||
| -6.27% | 3.01B | C- | ||
| -2.36% | 2.8B | B |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 3088 Stock
- Ratings MatsukiyoCocokara & Co.
